CASE REPORT
Effectiveness of rituximab in nephrotic syndrome treatment
Submission date: 2017-09-20
Final revision date: 2017-09-29
Acceptance date: 2017-10-02
Publication date: 2017-10-30
Cent Eur J Immunol 2017;42(3):313-317
KEYWORDS
ABSTRACT
Idiopathic nephrotic syndrome (INS) is a common chronic illness characterized by massive proteinuria and hypo-albuminemia in children. Baseline treatment is 6 month-corticotherapy. In cases of steroid resistant/dependent INS several types of treatment are used, including course of methyloprednisolone “pulses”, alkylating agents, cyclosporin A, levamisole and mycophenolate mofetil. It has been suggested that children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome had a significantly longer relapse-free period if rituximab (RTX) treatment was additionally applied. We present a case of a 4.5 boy who due to steroid-sensitive, steroid-dependent nephrotic syndrome has been successfully treated with RTX. Administration of the one dose of Rituximab in the patient caused immediate decrease of CD19/CD20 positive B lymphocyte population. The depletion of B cells has been observed for the next six months. With regard to the fact that RTX treatment may affect patient’s immune response, comprehensive immunodiagnostic has been conducted in a course of the Therapy.
REFERENCES (17)
1.
KDIGO Clinical Practice Guideline for Glomerulonephritis (2012): Kid Int Suppl 2012; 2.
2.
Machuca E, Esquivel EL, Antignac C. Idiopathic nephrotic syndrome in children: Genetic aspects. Niaudet P, Boyer O. Idiopathic nephrotic syndrome in children: Clinical aspects. In: Paediatric Nephrology. Avner ED, Harmon WE, Niaudet P, et al. (eds.). Springer-Verlag Berlin, Heidelberg 2009; 643-702.
3.
Pereira Wde F, Brito-Melo GE, Guimarães FT, et al. (2014): The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies. Inflamm Res 63: 1-12.
4.
Barnett HL, et al. (1981): Report of the International Study of Kidney Disease in Children. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr 98: 561-564.
6.
Cardarelli PM, Quinn M, Buckman D, et al. (2002): Binding to CD20 by anti-B1 antibody or F(ab’)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 51: 15-24.
7.
Pedersen IM, Buhl AM, Klausen P, et al. (2002): The chimeric anti-CD20 antibody Rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99: 1314-1319.
8.
Gürcan HM, Keskin DB, Stern JN, et al. (2009): A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9: 10-25.
10.
Benz K, Dötsch J, Rascher W, et al. (2004): Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19: 794-797.
11.
Gilbert RD, Hulse E, Rigden S (2006): Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 21: 1698-1700.
12.
Guigonis V, Dallocchio A, Baudouin V, et al. (2008): Rituximab treatment for severe steroid- or cyclosporin-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23: 1269-1279.
13.
Gulati A, Sinha A, Jordan SC, Hari P, et al. (2010): Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 5: 2207-2212.
14.
Kemper MJ, Gellermann J, Habbig S, et al. (2012): Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 27: 1910-1915.
15.
Iijima K, Sako M, NozuK, et al. (2014): Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384: 1273-1281.
16.
Ravani P, Ponticelli A, Siciliano C, et al. (2013): Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84: 1025-1033.
17.
Ravani P, Magnasco A, Edefonti A, et al. (2011): Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6: 1308-1315.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
